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Background 
Statin monitoring is the single largest reason for liver function testing (LFT) in people without known 
liver disease, usually ordered as an array of up to seven different tests.  Reduced testing using a single 
alanine transaminase test (ALT), would benefit patients at reduced cost. 
 
Aim  
To evaluate changes following an intervention to reduce the number and type of liver function tests 
ordered by general practitioners in people without liver disease. 
 
Design & Setting  
Cross-sectional time series in patients 30 years and over, comparing liver function testing by general 
practitioners in two east London Clinical Commissioning Groups (95 general practices with 650,000 
patients).    
 
Methods 
The intervention, available in only one CCG, consisted of development and dissemination of local 
stakeholder guidance on liver function testing for people prescribed statins and from 1 April 2015, 
access to a single ALT rather than full LFT array. Data were extracted monthly for one year before and 
one year after intervention. For one quarter evidence of pre-existing liver disease was assessed. 
 
Results 
Of the total population, 18.3% were on statins and they accounted for 45.5% of total LFTs. In the 
population without liver disease, liver function tests were 3.6 times higher for those on statins compared 
to those not on statins. 
 Following intervention there was a significant reduction in the full LFT array per 1000 people on 
statins, from 70.3 (95% CI 67.1 to 73.6) in the pre-intervention year, to 58.1 (95% CI 55.2 to 61.1) in 
the post-intervention year (p<0.001). The rate in the final quarter to March 2016 was 53.2 represented 
a reduction of 24.3% on the average pre-intervention rate. Although ALT use increased in people on 
statins in the intervention CCG, there was a reduction of 16.5% in total liver function tests (both full 
LFT and ALT).  
 
Conclusion  
Statins are the single largest reason for liver function testing. Guidance on testing combined with 
availability of a single ALT test, decreased full LFT aray testing in people on statins by 24% and total 
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liver function testing by 16.5%. This reduction represented a substantial cost saving and improved 
patient benefit. 
Key words 
Liver function test. Primary care. Inappropriate testing. Quality improvement. Diagnostic testing. 
Statins.   
 
How this fits in 
 Statins do not cause hepatotoxicity and current liver function monitoring is often unnecessary 
and costly.  
 Where testing is required a single ALT measurement is often sufficient (repeated once if on a 
high intensity statin). A single ALT test rather than the traditional full array of up to seven 
different liver function tests is sufficient for routine statin testing.  
 Local guidance on testing and availability of a single ALT test, reduced ordering of full array 
LFTs by 24% in people on statins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
Background 
Historically there have been concerns about possible hepatotoxicity of statins (HMG-CoA reductase 
inhibitors).1 However, more than thirty years use has confirmed that statins do not cause liver 
disease.2 Statins cause a mild and usually transient elevation of liver transaminases: typically less than 
three times the upper limit of normal with around 2% above that level.3-6 Statins are also likely to be 
beneficial in people with non-alcoholic fatty liver disease in whom cardiovascular disease is the 
commonest cause of death and statins are associated with reduced primary liver cancer.7 8 A UK 
health technology assessment confirmed ALT as one of the two most useful analytes for routine 
identification of liver disease.9 
 In 2012 the US Food and Drugs Administration changed product requirements for statins to 
recommend a single liver function test prior to starting statins and thereafter only if clinically 
indicated.10 11 Despite this reassurance, concern about raised transaminases has continued to act as one 
of the barriers to statin prescribing in the USA and a source of unnecessary liver function testing at 
high cost and potential patient harm from over-testing.2 12 13  
There are two issues with testing: one is the frequency of liver function tests for people on statins and 
the other is whether a full array of liver functions tests (LFTs) are routinely required. Frequency of 
monitoring was addressed in 2006 in the USA National Lipid Association's Statin Safety Task Force 
which recommended reduced liver function monitoring after starting a statin. A 2014 update by this 
Task Force confirmed that mild to modest elevations in liver enzymes were safe and did not cause 
liver disease.11 
In the UK the summary product characteristics (SPCs) for simvastatin 40mg, recommend testing 
before starting treatment and “… thereafter when clinically indicated”. For simvastatin 80mg testing 
at 3 months and periodically for the first year was advised.14 For atorvastatin, the SPC simply advises 
testing before starting and ”periodically thereafter”.15 In 2015, NICE quality standards advised the 
measurement of ALT before starting a statin, with a repeat ALT after 3 months treatment only for 
high intensity statins (atorvastatin 20mg, 40mg and 80mg and simvastatin 80mg and rosuvastatin 
10mg or more) and not again unless clinically indicated.16  
The second issue is the widespread use of a full array of up to seven different tests when clinicians 
request ‘LFTs’.  It is usually impossible to choose a single liver transaminase test on the electronic 
laboratory request forms which are currently used. Until recently, in two neighbouring CCGs in east 
London, Newham and Tower Hamlets served by the same hospital provider, the full array of up to 
seven different analytes was the only option. In 2014 a local consensus panel including hepatologists, 
general practitioners (GPs), prescribing advisors and laboratory staff, developed guidance for Tower 
5 
 
Hamlets CCG to promote the use of a single ALT test as sufficient to monitor statins, with a 
recommendation for a single ALT before starting but not again unless clinically indicated.17 18  The 
hospital laboratory provider enabled the ALT test to be ordered individually for these GPs in March 
2015 and the guidance was disseminated to all GPs in Tower Hamlets in April 2015. Neither the 
guidance or single ALT option was available in Newham. Tower Hamlets was the designated 
‘intervention’ CCG and Newham the ‘control’ CCG. The guidance was amended in October 2015 to 
include a single repeat test for people on high intensity statins to accord with the new NICE standards 
guidance. 
The aim of this study was to estimate the extent to which liver function testing was associated with 
statin use rather than known liver disease and to compare changes in the rate and type of liver 
function tests in people taking statins in the intervention and control CCGs. 
 
Methods 
The study conformed to the STROBE and RECORD guidance on reporting observational studies.19 20 
Data were taken from general practitioner electronic health records in 95 general practices serving a 
registered population of 650,000 patients in the inner east London CCGs of Tower Hamlets and 
Newham. All contributing practices used the same web-enabled record system (Egton Medical 
Information Services, EMIS) with agreed data entry templates ensuring consistent data entry and 
coding. All requests for these liver function tests were made by GPs and all results were obtained 
electronically. We did not include liver function tests ordered by hospital clinicians. All long-term 
statin prescriptions were electronically prescribed by GPs. Anonymised data were for the preceding 
month were extracted beginning 1st April 2014, with repeated extractions monthly until 1st April 
2016, 24 months in total.  
Anonymised data were obtained for all patients aged 30 or over, currently registered at the start of 
each month. Variables included statin prescription within 6 months prior to the search date, practice 
and CCG locality. A value and date were extracted for the ALT test. We assumed that where the dates 
for ALT and LFT were equal, the value for ALT was recorded as part of a full LFT array, rather than 
as a single analyte. A serum bilirubin test was used as a proxy indicator for LFT which designates a 
full array of seven different tests. Serum bilirubin values below 0.01 were excluded. For the last 
quarter prior to the intervention, ending March 2015, presence or absence of liver disease was 
collected as latest ever code of liver disease recorded. Counts of tests for both CCGs were combined 
for this quarter to investigate presence or absence of liver disease by statin prescription. 
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The intervention in Tower Hamlets CCG  in March 2015, consisted of enabling ordering of a single 
ALT on electronic systems and dissemination of locally developed guidance on liver function testing 
to all GPs.18  
The intervention aimed to achieve a reduction in the primary outcome, the rate of full array liver 
function tests in people on statins in the intervention CCG compared to the control CCG. Reduction in 
total liver function testing (both LFT and ALT) was a secondary outcome of interest.   
 
Regression analysis was used to assess differences in monthly trend for LFT and ALT per 1000 for 
the intervention CCG before and after the intervention. Differences in average testing in each CCG 
before and after the intervention was assessed. All analyses were conducted using Stata version 12.1. 
The p-values were two sided with statistical significance set at 0.05. 
 
Results 
Table 1 and Figure 1 show the number of LFTs and rate/1000 by statin and liver disease status for 
Newham and Tower Hamlets combined, for the three months ending March 2015. Liver disease was 
recorded in 2% (8,961/353,001) of the population and LFTs in these people accounted for 5.1% of all 
LFTs.  In those with liver disease 36.9% (3,304/8,961) were on statins and in those without liver 
disease 17.1% (58,981/344,040) were on statins.  
18.3% of the total population were on statins and they accounted for 45.5% of total LFTs. Patients on 
statins were 3.6 times more likely have LFTs than those not on statins. Of all patients on statins 25.4% 
(15,793/62,285) had LFTs recorded in the quarter compared to 7.1% (20,747/290,716) not on statins.  
 
Table 2 shows the numbers and rates/1000 population of the full LFT array and single ALT test for 
people on statins by CCG by month and Figure 2 illustrates this graphically.  
In Tower Hamlets LFTs for people on statins decreased significantly from an average rate per 1000 of 
70.3 (95% CI 67.1 to 73.6) in the pre-intervention year, to an average of 58.1 (95% CI 55.2 to 61.1) in 
the post-intervention year (p<0.001). The rate per 1000 in the final quarter to March 2016 was 53.2 
which represents a reduction of 24.3% on the average pre-intervention rate.  
Figure 3 shows LFT/1000 by month for people on statins in Tower Hamlets pre and post intervention 
and the fitted regression lines.  Before the intervention there was a monthly increase of 0.76% in 
LFT/1000. After the intervention the rate of LFTs decreased by 0.74% every month. The two slopes 
differed significantly (P=0.016, 95% Confidence Interval 0.31 to -2.68) and the test for difference 
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between the slope intercepts confirmed a significant reduction in LFT/1000 post-intervention (95% 
confidence interval -4.88 to – 21.32, P=0.003).  
In Newham, there was no significant decrease in LFTs in people on statins from an average of 
96.3/1000 (95%CI 93.0 to 99.5) to 92.9/1000 (95% CI 89.8 to 96.1) post-intervention (P=0.12).   
In Tower Hamlets the rate of total liver function testing (LFT+ALT) per 1000 reduced from an annual 
average pre-intervention of 78.2 (24769/ 316678) to 65.3 (18436/282377) post intervention, a 
reduction of 16.5% (12.9/78.21) (P<0.001) 
In the study CCGs a full LFT was priced at £45.50 and a single ALT at £6.50. In Tower Hamlets there 
were 3300 fewer full LFTs in the post-intervention than the pre-intervention year which represents a 
saving on the cost of testing alone of £150,150, less 3033 single ALT tests costing £19,714 which 
represents a decreased cost of £130,189. In Newham CCG there was an increase of 185 in full LFTs 
and 114 single ALT at a total increased cost of £9158.  
 
Discussion 
This study is the first of its kind to evaluate the impact of statin use on liver function testing in routine 
UK practice. We describe the changes that occurred in one CCG when new guidance on liver function 
testing and a single ALT test were made accessible to general practitioners. Although people on 
statins represented 18.1% of the total population, they accounted for almost half, 45.5%, of total liver 
function tests undertaken.  
By the end of the post-intervention year there was a 24.3% reduction in the full LFT array in people 
on statins in comparison to the year preceding the intervention. There was no significant decrease in 
Newham, the control CCG. There was also a significant reduction of 16.5% in total liver function 
tests (both LFT and ALT) in people on statins in Tower Hamlets. 
Comparison with previous literature Liver function testing for statin use is recognised as a 
substantial contributor to treatment costs in the UK.21 In Finland, an analysis of cost-effectiveness of 
statins for primary prevention gave monitoring costs for patients taking statins for primary prevention 
as 147.90 Euros [£108.59] per annum, based on one additional doctor consultation, nurse consultation 
and blood test per year.22 Lilford et al. have reviewed liver function testing in the  wider context of 
liver disease and also highlighted the cost implications of a reduced analyte panel.9 23 
Strengths and limitations 
The data was collected from 95 practices across the two CCGs and electronic recording of both 
prescribing and investigations ensured almost complete recording of data. Our results are an accurate 
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reflection of changes in liver function testing by GPs in an entire local area, not just selected practices. 
However, we did not include liver function testing undertaken by hospital clinicians and our results 
may underestimate the potential gains from adopting a single ALT for routine statin monitoring.  The 
CCGs studied are not representative of the UK as they serve populations who are exceptionally 
socially disadvantaged and ethnically diverse with high levels of cardiovascular disease, diabetes and 
high use of statins.24 However, the rate of liver function testing by general practitioner is unlikely to 
differ systematically to that in other areas in the UK. 
We were not able to directly ascribe all liver function testing in people on statins to the use of statins 
as testing occurs for other reasons including repeat testing due to abnormal test results. However, the 
3.6-fold increase in testing in people on statins without liver disease represents substantial additional 
testing associated with statin use. 
Implications for practice 
The price charged by different hospital trusts for laboratory testing varies substantially. The price of 
the full LFT analyte panel was £45.50 in Tower Hamlets and Newham CCGs. In Tower Hamlets 
approximately 20,000 LFTs were performed by general practitioners each year for statin monitoring 
at a cost per annum of £910,000. The intervention reduced the cost of LFTs by £130,89 and in the 
control CCG it increased by £9158. Additional savings are likely as practices make more use of the 
ALT-only option.  
It is beyond the scope of this paper to formally analyse the national costs of testing. However, the 
magnitude of these costs can be estimated, assuming a cost per full LFT array of £10, with 20,000 
tests in people on statins per CCG in each of the 209 CCGs in England costing £42 million per 
annum; a reduction of 20% in testing would save £8.4 million per year, offset by increases in ALT 
testing. These costs take no account of the costs of clinical consultation time associated with testing or 
phlebotomy. Reductions in cost would be sensitive to pricing of LFTs.  
Reducing the total number of full liver function tests carried out in patients on statins is likely to yield 
both clinical benefits and resource savings. For patients, fewer blood tests will result in fewer false 
positive results, unnecessary testing and patient anxiety. Reducing the total number of liver function 
tests ordered, and increasing the proportion that are ALT-only, decreases the cost of testing through 
reduced laboratory costs and reduced use of phlebotomist and clinical staff time.13 25 Almost 20 years 
ago, simple changes in test ordering were shown to have a dramatic impact on use.26 Enhanced 
feedback (publication of test requests per practice) and reminder messages may further improve the 
results. These each  achieved a 10% reduction in laboratory test ordering in a study in of 85 GP 
practices in North-East Scotland.27 There is much to suggest substantial overuse of a range of other 
common laboratory tests by both GPs and hospital clinicians than might be simply ameliorable with 
some systematic support.28 
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Conclusion 
Availability of an option to order a single ALT combined with guidance on testing in people on statins 
reduced full array LFT testing in the post-intervention year by 24% in people on statins. There was 
also a reduction of 16.5% in all liver function tests, both LFT and ALT, in people on statins in the 
intervention CCG. There was no significant change in testing in the control CCG.   
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TABLES AND FIGURES 
 
Table 1. Number of LFTs and rate per 1000 population by statin and liver disease status.  
Both CCGs quarter ending March 2015 
 
   Statin Population LFT  LFT/1000 
Liver Disease 
No 5,657 882 155.9 
Yes 3,304 965 292.1 
Total   8,961 1,847 206.1  
No Liver 
Disease 
No 285,059 19,865 69.7 
Yes 58,981 14,828 251.4 
Total   344,040 34,693 100.8  
 
Table 2. Number and rate per 1000 population by month. LFT and single ALT for people on statins; pre and post 
intervention by CCG.  
  
Tower Hamlets 
  
Newham 
Population LFT 
LFT 
/1000 
ALT 
alone 
ALT 
/1000 
Population LFT 
LFT 
/1000 
ALT 
alone 
ALT 
/1000 
Pre-intervention 
Apr 14 25,588 1,600 62.53 5 0.20 
 
34,529 3,029 87.72 8 0.23 
May 14 25,602 1,874 73.20 2 0.08 34,524 3,573 103.49 11 0.32 
Jun 14 25,645 1,934 75.41 4 0.16 34,602 3,664 105.89 14 0.40 
Jul 14 25,632 1,636 63.83 1 0.04 34,649 3,006 86.76 12 0.35 
Aug 14 25,623 1,671 65.21 2 0.08 34,717 3,268 94.13 16 0.46 
Sep 14 25,604 1,849 72.22 3 0.12 34,806 3,827 109.95 23 0.66 
Oct 14 25,628 1,827 71.29 1 0.04 34,835 3,798 109.03 16 0.46 
Nov 14 25,686 1,699 66.14 8 0.31 35,019 3,220 91.95 13 0.37 
Dec 14 25,727 1,617 62.85 3 0.12 35,316 2,949 83.50 13 0.37 
Jan 15 25,768 1,945 75.48 6 0.23 35,525 3,502 98.58 18 0.51 
Feb 15 25,874 1,876 72.51 0 0.00 35,795 3,180 88.84 7 0.20 
Mar 15 26,102 2,169 83.10 4 0.15 36,115 3,453 95.61 14 0.39 
Total   21,697  39   40,469  165  
Post-intervention 
Apr 15 26,082 1,688 64.72 88 3.37 
 
36,008 3,393 94.23 12 0.33 
May 15 26,105 1,528 58.53 174 6.67 36,021 3,407 94.58 16 0.44 
Jun 15 26,191 1,690 64.53 258 9.85 36,015 3,664 101.74 23 0.64 
Jul 15 26,241 1,524 58.08 209 7.96 36,212 3,365 92.92 17 0.47 
Aug 15 26,279 1,462 55.63 216 8.22 36,268 3,082 84.98 9 0.25 
Sep 15 26,629 1,529 57.42 315 11.83 36,280 3,601 99.26 24 0.66 
Oct 15 26,330 1,623 61.64 282 10.71 36,403 3,855 105.90 21 0.58 
Nov 15 26,442 1,532 57.94 283 10.70 36,568 3,294 90.08 16 0.44 
Dec 15 26,473 1,340 50.62 271 10.24 36,730 2,997 81.60 30 0.82 
Jan 16 26,528 1,516 57.15 310 11.69 36,792 3,376 91.76 34 0.92 
Feb 16 26,641 1,543 57.92 362 13.59 37,005 3,250 87.83 48 1.30 
Mar 16 26,737 1,422 53.18 304 11.37 37,204 3,370 90.58 29 0.78 
Total   18,397  3,072   40,654  279  
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 FIGURES 
Figure 1.  LFT/1000 by liver disease and statin status. Combined CCGs, quarter ending March 2015               
 
 
Figure 2:  LFT/1000 and ALT/1000 by month for people on statins in Tower Hamlets and Newham 
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Figure 3.  Fitted values for liver function testing by month in Tower Hamlets 
                 LFT/1000 for patients on statins pre and post intervention  
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